Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

NCT00920309 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
21
Enrollment
OTHER
Sponsor class

Stopped This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD

Conditions

Interventions

Sponsor

Yale University